Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M. File

Showing results (101-110 of 154) with videos related to

Pageof 16
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 31, 2020
Antibiotic Development Incentives That Reflect Societal Value of AntibioticsHelen W Boucher, Thomas M File, Vance G Fowler, et al.
BMC Pulmonary Medicine|May 9, 2021
Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbiditiesThomas M File, Elizabeth Alexander, Lisa Goldberg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 14, 2003
Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adultsLionel A Mandell, John G Bartlett, Scott F Dowell, et al.
Antibiotics (Basel, Switzerland)|December 24, 2021
Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 TrialsSusanne Paukner, David Mariano, Anita F Das, et al.
Proceedings of the American Thoracic Society|December 21, 2012
Reporting and publishing guidelines: article 12 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop reportKevin C Wilson, Richard S Irwin, Thomas M File, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 29, 2003
Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumoniaKevin B Anderson, James S Tan, Thomas M File, et al.
The Annals of Pharmacotherapy|February 13, 2014
Effect of introducing procalcitonin on antimicrobial therapy duration in patients with sepsis and/or pneumonia in the intensive care unitBryan M Bishop, John J Bon, Tamara L Trienski, et al.
Infection Control and Hospital Epidemiology|November 25, 2014
Guidance for the knowledge and skills required for antimicrobial stewardship leadersSara E Cosgrove, Elizabeth D Hermsen, Michael J Rybak, et al.
Future Microbiology|March 14, 2022
A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteriaSusanne Paukner, Gregory J Moran, Christian Sandrock, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 22, 2016
Approaches to Modifying the Behavior of Clinicians Who Are Noncompliant With Antimicrobial Stewardship Program GuidelinesEllie J C Goldstein, Debra A Goff, William Reeve, et al.
Pageof 16

Showing results (101-110 of 154) with videos related to

Sort By:
Pageof 16
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 31, 2020
Antibiotic Development Incentives That Reflect Societal Value of AntibioticsHelen W Boucher, Thomas M File, Vance G Fowler, et al.
BMC Pulmonary Medicine|May 9, 2021
Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbiditiesThomas M File, Elizabeth Alexander, Lisa Goldberg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 14, 2003
Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adultsLionel A Mandell, John G Bartlett, Scott F Dowell, et al.
Antibiotics (Basel, Switzerland)|December 24, 2021
Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 TrialsSusanne Paukner, David Mariano, Anita F Das, et al.
Proceedings of the American Thoracic Society|December 21, 2012
Reporting and publishing guidelines: article 12 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop reportKevin C Wilson, Richard S Irwin, Thomas M File, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 29, 2003
Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumoniaKevin B Anderson, James S Tan, Thomas M File, et al.
The Annals of Pharmacotherapy|February 13, 2014
Effect of introducing procalcitonin on antimicrobial therapy duration in patients with sepsis and/or pneumonia in the intensive care unitBryan M Bishop, John J Bon, Tamara L Trienski, et al.
Infection Control and Hospital Epidemiology|November 25, 2014
Guidance for the knowledge and skills required for antimicrobial stewardship leadersSara E Cosgrove, Elizabeth D Hermsen, Michael J Rybak, et al.
Future Microbiology|March 14, 2022
A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteriaSusanne Paukner, Gregory J Moran, Christian Sandrock, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 22, 2016
Approaches to Modifying the Behavior of Clinicians Who Are Noncompliant With Antimicrobial Stewardship Program GuidelinesEllie J C Goldstein, Debra A Goff, William Reeve, et al.
Pageof 16